Literature DB >> 16887239

Recombinant vaccines based on translocated effector proteins of Salmonella Pathogenicity Island 2.

Mohamed I Husseiny1, Florian Wartha, Michael Hensel.   

Abstract

Attenuated live Salmonella enterica are useful carriers for the delivery of heterologous antigens for vaccination. Effector proteins translocated by type III secretion systems (T3SS) of Salmonella have been successfully utilized for antigen delivery. Here we investigated the use of effector proteins of the T3SS encoded by Salmonella Pathogenicity Island 2 (SPI2). We observed that the effector protein SseF is suitable for delivery of various fusion proteins with heterologous antigens. The efficiency of this carrier protein was demonstrated in vaccination experiments with fusion proteins with Listeria monocytogenes protective antigens. SseF can thus be used as a versatile vehicle for translocation of heterologous proteins for vaccination.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16887239     DOI： 10.1016/j.vaccine.2005.11.020

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  15 in total

1.  Cloning and transfer of the Salmonella pathogenicity island 2 type III secretion system for studies of a range of gram-negative genera.

Authors:  James W Wilson; Clint Coleman; Cheryl A Nickerson
Journal:  Appl Environ Microbiol       Date:  2007-08-03       Impact factor: 4.792

2.  Proteomes of host cell membranes modified by intracellular activities of Salmonella enterica.

Authors:  Stephanie Vorwerk; Viktoria Krieger; Jörg Deiwick; Michael Hensel; Nicole Hansmeier
Journal:  Mol Cell Proteomics       Date:  2014-10-27       Impact factor: 5.911

3.  Efficacy of intracellular activated promoters for generation of Salmonella-based vaccines.

Authors:  Xin Xu; Mohamed I Husseiny; Andreas Goldwich; Michael Hensel
Journal:  Infect Immun       Date:  2010-08-23       Impact factor: 3.441

4.  Evaluation of Salmonella enterica type III secretion system effector proteins as carriers for heterologous vaccine antigens.

Authors:  Wael Abdel Halim Hegazy; Xin Xu; Leonid Metelitsa; Michael Hensel
Journal:  Infect Immun       Date:  2012-01-17       Impact factor: 3.441

5.  Systematic analysis of the SsrAB virulon of Salmonella enterica.

Authors:  Xin Xu; Michael Hensel
Journal:  Infect Immun       Date:  2009-10-26       Impact factor: 3.441

6.  Novel cancer vaccine based on genes of Salmonella pathogenicity island 2.

Authors:  Guosheng Xiong; Mohamed I Husseiny; Liping Song; Anat Erdreich-Epstein; Gregory M Shackleford; Robert C Seeger; Daniela Jäckel; Michael Hensel; Leonid S Metelitsa
Journal:  Int J Cancer       Date:  2010-06-01       Impact factor: 7.396

Review 7.  Salmonella enterica serovar Typhi live vector vaccines finally come of age.

Authors:  James E Galen; Marcela F Pasetti; Sharon Tennant; Patricia Ruiz-Olvera; Marcelo B Sztein; Myron M Levine
Journal:  Immunol Cell Biol       Date:  2009-05-05       Impact factor: 5.126

8.  Oral Salmonella msbB Mutant as a Carrier for a Salmonella-Based Vaccine for Prevention and Reversal of Type 1 Diabetes.

Authors:  Jacob Cobb; Jeffrey Rawson; Nelson Gonzalez; Michael Hensel; Fouad Kandeel; Mohamed I Husseiny
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

9.  Functional dissection of SseF, a membrane-integral effector protein of intracellular Salmonella enterica.

Authors:  Petra Müller; Deepak Chikkaballi; Michael Hensel
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

10.  Identification of salmonella pathogenicity island-2 type III secretion system effectors involved in intramacrophage replication of S. enterica serovar typhimurium: implications for rational vaccine design.

Authors:  Rita Figueira; Kathryn G Watson; David W Holden; Sophie Helaine
Journal:  mBio       Date:  2013-04-16       Impact factor: 7.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.